

FONDAZIONE CNAO  
CENTRO NAZIONALE DI ADROTERAPIA ONCOLOGICA  
rev. 0 del 4.8.2020

**AVVISO PER LA TRASPARENZA EX ANTE AI FINI DELLA REALIZZAZIONE DI UN PROGETTO DI COLLABORAZIONE SCIENTIFICA PER LA SPERIMENTAZIONE IN AMBITO CLINICO DELLA BORON NEUTRON CAPTURE THERAPY (BNCT)**

General Questions

- 1) What level of confidentiality will proposals have? Will they be shared publicly or shared with other applicants?  
**Confidentiality will be guaranteed, no public evidence and only CNAO will be aware of the content of the proposals.**
  
- 2) What is the timeline of the CNAO BNCT project? When does CNAO expect delivery of the BNCT system and when would clinical activities begin?  
**Cnao estimates a delivery of full system in 2 years from the beginning of the cooperation, i.e. second half of 2022; then will start the experimental pre-clinical phase, at the end of which will start the clinical use.**

With respect to item 2c:

- 3) We request clarification of the proposed use for the pharmacological laboratories.  
Is CNAO's intention:
  - a. To collaborate with the applicant on novel boron drug development
  - b. To carry out clinical testing of the novel boron drugs developed by the applicant
  - c. To use lab space provided by the applicant for its own boron carrier development

In the case of (a) or (c), could we have background information on the institute's drug development capabilities (or plans to enhance them)?

**CNAO has no internal capabilities nor plans to develop novel boron carriers. CNAO may be in the condition to set up collaborations with third Parties to develop a novel boron carrier and in this case the applicant will be requested to participate to these collaborations to be agreed in due time. In any case, CNAO intends to actively collaborate to the pre-clinical (radiobiological) and clinical testing of any boron carrier.**

Pavia, 4.8.20

IL R.U.P.

Dott. Sandro Rossi